Currently, there are 186.96M common shares owned by the public and among those 139.88M shares have been available to trade.
The company’s stock has a 5-day price change of 2.81% and 89.20% over the past three months. TSHA shares are trading 127.68% year to date (YTD), with the 12-month market performance up to 426.80% higher. It has a 12-month low price of $0.50 and touched a high of $4.32 over the same period. TSHA has an average intraday trading volume of 2.45 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.08%, 36.08%, and 66.85% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Taysha Gene Therapies Inc (NASDAQ: TSHA) shares accounts for 69.91% of the company’s 186.96M shares outstanding.
It has a market capitalization of $753.69M and a beta (3y monthly) value of 0.49. The earnings-per-share (ttm) stands at -$1.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.28% over the week and 7.42% over the month.
Earnings per share for the fiscal year are expected to increase by 56.63%, and -14.19% over the next financial year.
Looking at the support for the TSHA, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on April 09, 2024, with the firm’s price target at $9. Jefferies coverage for the Taysha Gene Therapies Inc (TSHA) stock in a research note released on February 01, 2023 offered a Hold rating with a price target of $1.50. Morgan Stanley was of a view on January 27, 2023 that the stock is Equal-Weight, while Goldman gave the stock Neutral rating on November 09, 2022, issuing a price target of $16- $3. Robert W. Baird on their part issued Outperform rating on March 09, 2022.
